Keywords: indevus, licenses, european, sanctura, xr, rights, madaus
Indevus licenses European Sanctura XR rights to Madaus
Article | 13 November 2006
The USA's Indevus Pharmaceuticals has licensed the rights to sell Sanctura XR (trospium Cl), the once-daily formulation of its currently-marketed ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
